Find stores and restaurants, hours, and event schedules with this new app. Photo courtesy of M-K-T Heights

Bustling mixed-use Heights development M-K-T (600 N Shepherd Dr.) has been all the buzz lately, with new hip fashion shops such as Nollege and TAFT strolling in and Homestead Breakfast, Lunch & Later serving up breakfast to hungry shoppers. A recent opening party for Chloe Dao's new locale was all the rage on local IG stories.

Now, more good news for M-K-T shoppers: the center has announced a new mobile app, which helps visitors locate a retailer, easily check for upcoming events, or quickly look at what time their favorite restaurant or retailer is opening.

Users can download the app, created by Triten Real Estate Partners, here.

The new app (available for both Apple and Android users ) boasts a full directory of on-site retailers, wellness, restaurants, and corporate headquarters, according to a release. Location-aware maps help users navigate the development and scan images, descriptions, and store hours for each on-site business.

A full, up-to-date calendar of M-K-T's events will help plan what to where and when for scenesters.

"An over 200,000 square foot property can be intimidating to visitors and sometimes walkup signage and printed directories aren't enough", said Lisa Reyerse, marketing and brand director at Triten Real Estate Partner, in a statement.

"The M-K-T Heights mobile app allows our visitors to always have an up-to-date property directory, location-aware map, and a full calendar of on site events in their pocket at all times. The app is simple and easy to use, yet robust with information that our visitors need to help navigate and enjoy their time at M-K-T."

After being announced a few years ago, the M-K-T has slowly opened its stores and eateries over the past several months.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”